Document Detail


Novel Extracellular Matrix Biomarkers as Predictors of Adverse Outcome in Chronic Heart Failure: Association between Biglycan and Response to Statin therapy in the CORONA trial.
MedLine Citation:
PMID:  25451704     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: The extracellular matrix (ECM) plays an important role in left ventricular remodeling and progression of heart failure (HF). Biglycan and mimecan are ECM proteins that are abundantly expressed in cardiac tissue but have not been evaluated as prognostic markers in HF. We investigated their interaction with statin treatment and association with adverse outcome in chronic HF.
METHODS AND RESULTS: The association between serum levels of biglycan and mimecan and the primary endpoint (cardiovascular (CV) death, nonfatal myocardial infarction, nonfatal stroke), all-cause mortality, CV death, the composite of all-cause mortality/hospitalization for worsening of HF or the coronary endpoint was evaluated in 1390 patients >60 years of age with ischemic systolic HF in the Controlled Rosuvastatin Multinational Trial in HF (CORONA) population, randomly assigned to 10 mg rosuvastatin or placebo. Serum biglycan and mimecan added no prognostic information beyond conventional risk factors including NT-proBNP. However, statin treatment improved all outcomes except CV death in patients with low biglycan levels (i.e. lower tertile), even after full multivariable adjustment.
CONCLUSIONS: Although circulating levels of mimecan and biglycan were of limited predictive value in patients with chronic HF, circulating biglycan could be a useful marker for targeting statin therapy in patients with HF.
Authors:
Thor Ueland; Pål Aukrust; Ståle H Nymo; John Kjekshus; John J V McMurray; John Wikstrand; Dirk Block; Christian Zaugg; Lars Gullestad
Related Documents :
25398044 - Recent evolutions in pediatric and congenital echocardiography.
1286184 - The role of endotoxin in the pathogenesis of experimental multiple system organ failure...
25217434 - Management strategies for heart failure with preserved ejection fraction.
25450324 - Right ventricular infarction and mitral stenosis: a resuscitation challenge.
10029124 - Geographic variation in the treatment of acute myocardial infarction: the cooperative c...
3180394 - Percutaneous cardiopulmonary bypass limits myocardial injury from ischemic fibrillation...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-7
Journal Detail:
Title:  Journal of cardiac failure     Volume:  -     ISSN:  1532-8414     ISO Abbreviation:  J. Card. Fail.     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-12-2     Completed Date:  -     Revised Date:  2014-12-3    
Medline Journal Info:
Nlm Unique ID:  9442138     Medline TA:  J Card Fail     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Plasma Ultrasensitive Cardiac Troponin During Long-term Follow-up of Heart Transplant Recipients.
Next Document:  Prognostic Impact of Central Sleep Apnea in Patients with Heart Failure.